Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real World Study of Ensartinib in Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

NCT05498064 is registered in ClinicalTrials.gov with Peking Union Medical College Hospital as lead sponsor.

NCT NCT05498064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05498064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real World Study of Ensartinib in Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Lead sponsor
Peking Union Medical College Hospital
Phase
Observational
Overall status
Recruiting
Start date
May 13, 2022
Completion date
December 1, 2028
Enrollment
490 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic lymphoma kinase i1171n, carcinoma, non-small-cell lung, ensartinib